Prot #GS-US-367-1170: A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antivi

Project: Research project

Project Details

StatusFinished
Effective start/end date1/25/161/25/19

Funding

  • PRA Health Sciences (GS-US-367-1170)
  • Gilead Sciences, Inc. (GS-US-367-1170)